Episode Details

The researchers say that the one-time therapy gives a working copy of that gene to the inner ear during a medical operation. Most of the children were treated in one ear, although one child in the two-person study was treated in both ears.

研究人员说，一次性疗法在医疗操作过程中将该基因的工作副本赋予了内耳。 尽管两人的研究中的一个孩子在两个耳朵中都接受了治疗，但大多数孩子都被一只耳朵接受治疗。

The study with six children took place at Fudan University in Shanghai. Dr. Yilai Shu helped lead the study and trained in Chen’s laboratory. Chen was involved in the research. Chinese science organizations and biotechnology company Shanghai Refreshgene Therapeutics helped provide financial support.

 与六个孩子的研究在上海的福丹大学进行。 Yilai Shu博士帮助领导了这项研究，并接受了Chen的实验室的培训。 陈参与了研究。 中国科学组织和生物技术公司上海刷新的治疗学有助于提供财务支持。

Researchers observed the children for about six months. They do not know why the treatment did not work in one of them. But the five others, who were completely deaf, can now hear a normal discussion, the researchers said. 

研究人员观察到孩子大约六个月。 他们不知道为什么治疗在其中一种中没有起作用。 研究人员说，但是五个完全聋哑的五个人现在可以听到正常的讨论。 

Chen estimated they now hear at a level 60 percent to 70 percent of normal. The therapy caused no major side effects. 

陈估计他们现在听到的是正常水平的60％至70％。 该疗法没有引起重大副作用。

Early results from other research have shown similar results. 

其他研究的早期结果显示出相似的结果。

Regeneron Pharmaceuticals is a biotech company based in New York state. It announced in October that a child under two years old showed improvements six weeks after gene therapy. The results came from a study Regeneron did with support from Decibel Therapeutics, a company in Boston. 

Regeneron Pharmaceuticals是一家位于纽约州的生物技术公司。 它在十月份宣布，两岁以下的儿童在基因治疗六周后表现出改善。 结果来自Regeneron在波士顿公司的Decibel Therapeutics的支持下进行的研究。 

Listen Now